Summary of Clinical Practice Guideline

Newborn Hearing Screening Programme (UK)

Newborn Hearing Screening and Assessment: Guidelines for Surveillance and Audiological Monitoring of Infants and Children following the Newborn Hearing Screen
Wood, S., Foley, R., et al. (2010).
In G. Sutton (Ed.), England: National Health Service Antenatal and Newborn Screening Programmes, 15 pages.

AGREE Rating: Recommended with Provisos

This guideline provides recommendations on the early identification, surveillance, and monitoring of children with permanent hearing loss in the neonatal period.


Permanent Childhood Hearing Loss

  • Screening/Assessment

    • Screening

      • Risk Factors/Surveillance

        • Children with microtia/atresia (no patent ear canal in one or both ears) or neonatal Meningitis (confirmed or strongly suspected bacterial meningitis or septicaemia) should not receive a newborn screen. “Screening is inappropriate for these babies because those with microtia/atresia will always have a degree of loss, and the risk of SNHL following bacterial meningitis is very high…These children should be immediately referred by the Paediatrician to Audiology and given an early hearing assessment (usually ABR) within 4 weeks of discharge from hospital” (p. 7).

        • The following groups require targeted follow-up and should be seen for behavioral testing at 8 months of age:

          • Those that declined or did not complete the newborn screen or follow-up.

          • Children with conditions associated with hearing loss including syndromes (e.g., Down’s, Turner’s), cleft palate, or other cranio-facial abnormalities.

          • Children with high-risk factors for late-onset or progressive deafness specifically family history, severe jaundice, mechanical ventilation or ECMO, prolonged NICU stay with clear ABR response but no OAE response, or neuro-degenerative/developmental disorders.

          • Children with suspected or confirmed A155G mitochondrial mutation who have received ototoxic drugs or those who have received ototoxic drugs outside of the therapeutic range.

Deafness, Hearing Loss, Early Hearing Detection and Intervention

» Access the Guideline